CGTX — Cognition Therapeutics Share News
0.000.00%
Last trade - 00:00Cognition Therapeutics rises on FDA support for late-stage trials of Alzheimer’s drug
Cognition Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Cognition Therapeutics Q2 net loss narrows to $6.7 mln
Cognition Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Cognition Therapeutics Completes FDA End-of-Phase 2 Meeting For Zervimesine In Alzheimer’s
Brief: Cognition Therapeutics Study Of Zervimesine (CT1812) In Early Alzheimer’s Disease Surpasses 50% Enrollment Target
Brief: Cognition Therapeutics Provides Regulatory Update On Zervimesine In Alzheimer’s Disease
Cognition Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Cognition Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview
Cognition Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Cognition Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-BioAge Labs, Expedia, Citizens Financial Group
U.S. STOCKS ON THE MOVE-American Battery Technology, Ollie's Bargain Outlet, BioAge Labs
U.S. STOCKS ON THE MOVE-Cognition Therapeutics, Oklo, Jabil
Cognition Therapeutics rises as dementia drug meets main goal in mid-stage trial
Brief: Cognition Therapeutics Announces All Participants Have Completed Their Final Visits
Brief: Cognition Therapeutics’ Analysis Correlates Biomarker Changes With Cognitive Benefit In Alzheimer’S Population
U.S. STOCKS ON THE MOVE-NetEase, Wolfspeed, B. Riley
U.S. STOCKS ON THE MOVE-Evogene, Stryker, Opera